Paul Freel
Family Medicine · Dillon, SCNPI 1528088721
Payments from drug & device makers
Across 229 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$471
- Lilly USA, LLC$344
- Amgen$324
- AbbVie$300
- GSK$154
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$153
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,26499%
- Education$221%
- Other$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $471 |
| Lilly USA, LLC | 26 | $344 |
| Amgen | 12 | $324 |
| AbbVie(2 entities) | 25 | $300 |
| GSK | 10 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $153 |
| Sanofi-aventis U.S. LLC | 10 | $136 |
| Novartis | 8 | $125 |
| Amarin Pharma, Inc. | 8 | $125 |
| Merck | 15 | $114 |
| Pfizer | 7 | $87 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 4 | $77 |
| AstraZeneca | 6 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Johnson & Johnson | 4 | $58 |
| Abbott | 3 | $57 |
| Astellas Pharma US Inc | 4 | $56 |
| Eisai Inc. | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Intuity Medical Inc | 1 | $24 |
| Mylan Specialty L.p. | 2 | $23 |
| Inari Medical, Inc. | 1 | $22 |
| Forte Bio-pharma LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Bayer | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$105
How this compares
$3,302 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $104,058 |
| JardianceEmpagliflozin | 78 | $89,793 |
| EliquisApixaban | 63 | $70,943 |
| TrulicityDulaglutide | 27 | $31,231 |
| MounjaroTirzepatide | 26 | $31,023 |
| JanuviaSitagliptin Phosphate | 18 | $24,917 |
| RybelsusSemaglutide | 16 | $23,773 |
| XareltoRivaroxaban | 22 | $20,073 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $18,479 |
| FarxigaDapagliflozin Propanediol | 20 | $17,935 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,337 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $8,372 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,285 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,554 |
| NexletolBempedoic Acid | 11 | $5,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $471 | $127,83184 claims |
| Boehringer IngelheimJardiance | $62 | $89,79378 claims |
| PfizerEliquis | $87 | $70,94363 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $344 | $62,25553 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $154 | $26,76432 claims |
| MerckJanuvia | $114 | $24,91718 claims |
| AstraZenecaFarxiga, Symbicort | $73 | $21,24435 claims |
| Johnson & JohnsonXarelto | $58 | $20,07322 claims |
| Esperion Therapeutics, Inc.Nexletol | $25 | $5,00911 claims |
| AbbVieSynthroid | $300 | $3,38043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Dillon
- Timothy FitzgibbonDillon$30K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.